Cefozopran hydrochloride (SCE-2787 hydrochloride) is a fourth-generation cephalosporin. is a cell wall biosynthesis inhibitor with a broad spectrum of activity against Gram-positive and Gram-negative bacteria.

Cefozopran hydrochloride (SCE-2787 hydrochloride), a fourth-generation cephalosporin, exhibits substantial activity against a range of bacteria. Cefozopran hydrochloride is effective against gram-positive organisms, including methicillin-susceptible staphylococci, enterococci, and viridans group streptococci. Additionally, Cefozopran hydrochloride demonstrates efficacy against gram-negative organisms such as Hemophilus influenza. Notably, Cefozopran hydrochloride displays comparatively good activity against enterococci and P. aeruginosa, which are typically resistant to other cephalosporins[2].

In four-week-old ICR male mice, Cefozopran hydrochloride, administered subcutaneously at doses ranging from 5 to 80 mg/kg twice a day for 5 days, proves effective against acute respiratory tract infections caused by Kiebsiella pneumonia DT-S. In a model of chronic respiratory tract infection induced by K. pneumoniae 27, Cefozopran hydrochloride, at doses between 20 and 80 mg/kg administered subcutaneously twice a day for 7 days in five-week-old CBA/J female mice, exhibits effectiveness comparable to Ceftazidime[2].